Aa
A
A
Close
Avatar_universal
a little Roche data
"ZURICH, Nov 2 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX: Quote, Profile, Research) says it has moved its investigational hepatitis C drug R1626 into a new mid-stage trial after it showed promising results in combination with two of its other medicines.

Roche said on Friday the hepatitis C virus could no longer be detected in up to 81 percent of patients after four weeks of treatment with R1626, in combination with Pegasys and Copegus.

Based on the results of the Phase IIa study, Roche will move R1626 into a Phase IIb trial.

In a separate statement on Friday Roche also said a Pegasus and Copegus combination had shown benefits in patients who did not respond to initial treatment with Schering Plough Corp's (SGP.N: Quote, Profile, Research) Pegintron."
Cancel
5 Answers
Page 1 of 1
233616_tn?1312790796
Comment
Cancel
233616_tn?1312790796
Comment
Comment
Submit Comment
233616_tn?1312790796
woo hoo...the race is on, better than teleprivir....by 6 percent....hope the numbers are right.

has anyone toyed with extra zinc for it's replication inhibiting qualities? it's cheap and known to inhibit virus's.
Comment
Cancel
233616_tn?1312790796
Comment
Comment
Submit Comment
264121_tn?1313033056
Do you have any idea what the dosage levels of the combo of pegasys/riba and alinia were in the trials and for how long the subjects were treated?
Comment
Cancel
264121_tn?1313033056
Comment
Comment
Submit Comment
Avatar_universal
article came out latter, a tiny bit more detail

"Roche Issues Hepatits Drug Data
By Elizabeth Trotta
Staff Reporter
11/2/2007 6:00 PM E

"Roche said Friday that in a phase IIa study a triple-drug combination for treatment of hepatitis C showed a robust virological response and subsequently will proceed to a phase IIb study.
Presenting results at the American Association of the Study of Liver Diseases (AASLD) meeting in Boston, the Swiss drugmaker said its investigational hepatitis C drug R1626 showed promising antiviral activity in the phase IIa trial when given with Pegasys (peginterferon alfa-2a) and Copegus. The aforementioned Roche drugs are used together to treat adults with chronic hepatitis C whose liver still works normally and who haven't been previously treated with an interferon alpha.

After four weeks of treatment with the three-drug combination, the virus couldn't be detected in 81% of patients with a mean decrease in viral load of 5.2 log10 from the baseline, and Roche said most adverse events were mild to moderate.

((((((((Also, no resistance to R1626 was identified following intensive testing for either two weeks of treatment with R1626 as monotherapy or in patients treated with R1626 for four weeks in combination with the standard of care. +++thought this was important)))))))))

The phase IIb study, called POLI 1, which will further investigate R1626 in ((((((((combination with standard or lower dose of Pegasys and standard dose of Copegus++++doesn't look like their interested in the lowering of riba dose)))))))), is now open and enrolling patients in eight countries, including the U.S.
Pharmasset , which partners with Roche to develop chronic hepatitis C drug R7128, presented data Friday on a phase I 14-day monotherapy study of patients who failed to respond to standard therapy. Pharmassest said there was a 99% mean decrease in HCV (((((((with no serious adverse events. ++++++important))))))))(Pharmasset divulged positive preliminary results for the study in September.) The companies are hoping those results will translate when the drug is used in combination with other therapies for a longer duration in a previously untreated population

alagirl, no Alinia in this trial. I believe peg/riba dosing was standard for the Roche SOC products.

Merrybe, I seem to cross paths with you every morning (4:30 am my time) you must be a late owl, or early owl like me (lol)
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
The only 4 week RVr data from Vertex I have seen was from EASL and showed 88% success measured at less than 30 and 79% at less than 10.  The Roche study doesn't show what measurement they were using.  But their 81% is either 7% worse or 2% better, unless you have some different Vertex data.
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Your Answer
Avatar_universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
a little Roche data
Submit Answer
A
A
Recent Activity
4059843_tn?1454481984
Blank
mishymoshymarcy commented on need a title -
9 hrs ago
134578_tn?1446090952
Blank
AnnieBrooke commented on need a title -
9 hrs ago
3060903_tn?1398568723
Blank
Blank
Weight Tracker
Track your weight over time
Start Tracking Now
Top Hepatitis Answerers
446474_tn?1446351282
Blank
San Francisco, CA
1815939_tn?1377995399
Blank
317787_tn?1428318779
Blank
DC
Avatar_universal
Blank
163305_tn?1333672171
Blank
Rural Mural, CA
683231_tn?1438659664
Blank
Auburn, WA
Hepatitis C Community Resources
RSS Expert Activity
233488_tn?1310696703
Blank
Marathon Running Done Over Many Yea...
May 21 by John C Hagan III, MD, FACS, FAAOBlank
233488_tn?1310696703
Blank
New Article on Multifocal IOL vs &q...
May 21 by John C Hagan III, MD, FACS, FAAOBlank
748543_tn?1443740527
Blank
TMJ/TMJ The Connection Between Teet...
01/15 by Hamidreza Nassery , DMD, FICOI, FAGD, FICCMOBlank
Top Hepatitis Answerers
446474_tn?1446351282
Blank
San Francisco, CA
1815939_tn?1377995399
Blank
317787_tn?1428318779
Blank
DC
Avatar_universal
Blank
163305_tn?1333672171
Blank
Rural Mural, CA
683231_tn?1438659664
Blank
Auburn, WA